Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients

被引:21
|
作者
Toth, Kinga [1 ]
Patai, Arpad V. [1 ]
Kalmar, Alexandra [1 ,2 ]
Bartak, Barbara Kinga [1 ]
Nagy, Zsofia Brigitta [1 ]
Galamb, Orsolya [2 ]
Wichmann, Barnabas [2 ]
Tulassay, Zsolt [1 ,2 ]
Molnar, Bela [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Internal Med 2, Szentkiralyi Utca 46, H-1088 Budapest, Hungary
[2] Hungarian Acad Sci, Mol Med Res Unit, Budapest, Hungary
关键词
SEPT9; Colorectal cancer; Tumormarkers; Circadian rhythm; Cell-free DNA; BREAST-CANCER; CLOCK; PLASMA; BLOOD; PROGRESSION; EXERCISE; INFLAMMATION; CORTISOL; BEHAVIOR; SLEEP;
D O I
10.1007/s12253-016-0174-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the level of cell-free DNA (cfDNA), Septin 9 (SEPT9) and tumor markers (CEA, AFP, CA19-9, TPA, CA72-4). Plasma samples were collected four times a day (06:00, 12:00, 18:00, 24:00) from 9 patients with CRC (5 stage I-II, 4 stage III-IV), from one with colorectal adenoma and from one healthy control. CfDNA was isolated, quantified and bisulfite-converted. CfDNA and methylated SEPT9 were determined by RT-PCR. Plasma levels of conventional tumor markers were also measured. The lowest cfDNA concentrations were observed at 24:00 and 18:00 in stage I-III patients. In stage IV samples low cfDNA level (mean 48.2 ng/ml) were observed at several time points (6:00, 12:00, 18:00). The highest cfDNA levels were measured at 6:00 and 12:00 in CRC I-III stages and at 24:00 in stage IV samples (78.65 ng/ml). Higher in-day differences were found in stage II (43-48%) than in stage I samples (22%). Interestingly, the highest SEPT9 methylation level was found at 24:00 in most CRC cases, in contrast to the cfDNA levels. At 24:00, all cancer and adenoma cases were positive for SEPT9 methylation. At other time points (6:00, 12:00, 18:00) only 77.7% of CRC samples showed SEPT9 positivity. Stage I samples were SEPT9 positive only at 24:00. CEA and CA19-9 levels displayed correlation with the amount of cfDNA in case of late stage cases. Daytime activity can influence SEPT9 positivity in cases with low concentration of cfDNA. Thus, it may improve screening sensitivity by collecting samples earlier in the morning.
引用
收藏
页码:699 / 706
页数:8
相关论文
共 50 条
  • [31] Cell-free circulating tumor DNA in cancer
    Qin, Zhen
    Ljubimov, Vladimir A.
    Zhou, Cuiqi
    Tong, Yunguang
    Liang, Jimin
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [32] The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis
    Basnet, Shiva
    Zhang, Zhen-yu
    Liao, Wen-qiang
    Li, Shu-heng
    Li, Ping-shu
    Ge, Hai-yan
    JOURNAL OF CANCER, 2016, 7 (09): : 1105 - 1113
  • [33] Clinical utility of circulating cell-free DNA in advanced colorectal cancer
    Pereira, Allan A. Lima
    Morelli, Maria Pia
    Overman, Michael
    Kee, Bryan
    Fogelman, David
    Vilar, Eduardo
    Shureiqi, Imad
    Raghav, Kanwal
    Eng, Cathy
    Manuel, Shanequa
    Crosby, Shadarra
    Wolff, Robert A.
    Banks, Kimberly
    Lanman, Richard
    Talasaz, AmirAli
    Kopetz, Scott
    Van Morris
    PLOS ONE, 2017, 12 (08):
  • [34] Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology
    Bosque, Javier
    Guirao, Carlos
    Ferrandez, Asia
    Suarez, Noelia
    Isabel Castillejo, Maria
    Anguita, Diana
    Pamies, Maria
    Moya, Alejandro
    Luis Soto, Jose
    Gallego Plazas, Javier
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (10) : 1924 - 1931
  • [35] Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor
    Leerhoff, Sabine
    Raem, Arnold
    Kolbe, Ernst-Wolfgang
    Schulz, Laura
    Borchers, Kirsten
    Koehler, Thomas
    Winde, Guenther
    Kirchner, Carmen
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 36
  • [36] Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology
    Javier Bosque
    Carlos Guirao
    Asia Ferrández
    Noelia Suarez
    Maria Isabel Castillejo
    Diana Anguita
    María Pamies
    Alejandro Moya
    José Luis Soto
    Javier Gallego Plazas
    Clinical and Translational Oncology, 2022, 24 : 1924 - 1931
  • [37] Alu-based cell-free DNA: A potential complementary biomarker for diagnosis of colorectal cancer
    Qi, Jing
    Qian, Chen
    Shi, Wei
    Wu, Xinhua
    Jing, Rongrong
    Zhang, Lurong
    Wang, Zhiwei
    Ju, Shaoqing
    CLINICAL BIOCHEMISTRY, 2013, 46 (1-2) : 64 - 69
  • [38] Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients
    Hendriks, Rianne J.
    Dijkstra, Siebren
    Smit, Frank P.
    Vandersmissen, Johan
    Van de Voorde, Hendrik
    Mulders, Peter F. A.
    van Oort, Inge M.
    Van Criekinge, Wim
    Schalken, Jack A.
    PROSTATE, 2018, 78 (05) : 336 - 342
  • [39] Oncological Assessment of Stent Placement for Obstructive Colorectal Cancer from Circulating Cell-Free DNA and Circulating Tumor DNA Dynamics
    Takahashi, Goro
    Yamada, Takeshi
    Iwai, Takuma
    Takeda, Kohki
    Koizumi, Michihiro
    Shinji, Seiichi
    Uchida, Eiji
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (03) : 737 - 744
  • [40] Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA
    Barefoot, Megan E.
    Loyfer, Netanel
    Kiliti, Amber J.
    McDeed, A. Patrick
    Kaplan, Tommy
    Wellstein, Anton
    FRONTIERS IN GENETICS, 2021, 12